Enabled by POZ

We are developing proprietary drugs to treat neurological diseases. Our lead product candidate, SER-252 for advanced Parkinsons Disease, is anticipated to enter clinical trials in 2025. Our current discovery and development work includes a focus on unlocking the potential of cannabinoids and other molecules across a range of CNS indications and beyond. Our POZ platform partners are at the forefront in advancing novel RNA medicines in vaccine immunology, cancer immunoRX, and gene therapy.

Small Molecules

Drug Candidate
Indication
Research
Preclinical
Phase 1
Phase 2
Phase 3
SER-252(POZ-apomorphine)
Advanced Parkinson’s
IND-enabling studies
SER-2xx(POZ-cannabinoids)
Undisclosed Indications
Proof of Concept
SER-2xx(POZ-undisclosed)
Cardiovascular Disease
Proof of Concept

Platform Partnering Programs

Drug Candidate
Indication
Research
Preclinical
Phase 1
Phase 2
Phase 3
POZ-RNA
RNA therapeutics
R&D with partners
POZ-ADCs
Oncology
Proof of Concept

Join Us.

We’re pioneering bold new science.

Partners Investors Contact